Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...
He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
Key Takeaways Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, ...
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback